Report #2849265

Received Jul 10, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Unknown
Age: Age unknown
State: —
Recovered: Unknown
Vaccinated: —
Onset: —
Days to onset: —
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
RSV	RSV (AREXVY)	GLAXOSMITHKLINE BIOLOGICALS	UNK	UNK	—

Symptoms (1)

Injection site pruritus

Symptom narrative

Itching at injection site; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of injection site itching in a patient who received RSVPreF3 adjuvanted (Arexvy) for prophylaxis. On an unknown date, the patient received Arexvy. On an unknown date, an unknown time after receiving Arexvy, the patient experienced injection site itching (Verbatim: Itching at injection site). The outcome of the injection site itching was not reported. It was unknown if the reporter considered the injection site itching to be related to Arexvy. It was unknown if the company considered the injection site itching to be related to Arexvy. Additional Information: GSK Receipt Date: 26-JUN-2025 This case was reported by a patient via interactive digital media. The patient received the Arexvy vaccine and experienced itching at the injection site.